查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1937771

全球融合切片檢查市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Fusion Biopsy Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 174 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

融合切片檢查市場規模預計將從 2025 年的 14.5 億美元成長到 2034 年的 29.8 億美元，2026 年至 2034 年的複合年成長率為 8.3%。

融合切片檢查市場正經歷顯著成長，這主要得益於影像技術的進步和前列腺癌發病率的上升。融合切片檢查結合了傳統超音波影像和磁振造影（MRI），提高了前列腺癌診斷的準確性。這項創新技術能夠對可疑病灶進行標靶取樣，在提高臨床顯著癌症檢出率的同時，最大限度地減少不必要的切片檢查。隨著人們對前列腺癌的認知不斷提高以及篩檢指南的不斷完善，預計對融合切片檢查的需求將持續成長，從而推動該市場強勁發展。

此外，對個人化醫療的日益重視正在影響融合切片檢查的發展趨勢。提供更精確的腫瘤特徵訊息，使醫療專業人員能夠為每位患者制定個人化的治療方案。這種向標靶治療的轉變在腫瘤學領域尤其重要，因為了解腫瘤的特定生物學特徵會顯著影響治療結果。隨著醫療系統擴大採用精準醫療方法，融合切片檢查市場有望受益於先進診斷工具的整合，從而改善患者照護並最佳化資源利用。

此外，微創手術的興起也推動了融合切片檢查技術的應用。患者越來越傾向於選擇能夠減少不適感和縮短恢復時間的治療方案，這使得融合切片檢查成為傳統切片檢查方法的理想替代方案。使用者友善設備的研發以及針對醫療專業人員的培訓計畫也進一步促進了這項技術的應用。隨著融合切片檢查市場的不斷發展，持續的研發將在拓展其應用範圍和提高診斷準確性方面發揮關鍵作用，最終有助於改善前列腺癌患者的治療效果。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 繪製滲透率和成長前景圖
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制
    • 市場機遇
    • 市場問題
  • 波特五力分析
  • PESTLE分析

第4章 全球融合切片檢查市場（依技術目標分類）

  • 市場分析、洞察與預測
  • DNA
  • RNA
  • 蛋白質

5. 全球融合切片檢查市場（依產品分類）

  • 市場分析、洞察與預測
  • 多基因檢測
  • 單基因檢測
  • 伴隨診斷
  • 調查工具包（僅供參考）

6. 全球融合切片檢查市場（按應用領域分類）

  • 市場分析、洞察與預測
  • 腫瘤學
  • 神經病學
  • 感染疾病
  • 心血管疾病

7. 全球融合切片檢查市場（依技術分類）

  • 市場分析、洞察與預測
  • 次世代定序（NGS）
  • 聚合酵素鏈鎖反應（PCR）
  • 數位PCR
  • 奈米弦技術

8. 全球融合切片檢查市場（按地區分類）

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商格局（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • HologicInc
    • Exact Sciences Corporation
    • Myriad GeneticsInc
    • BioRad LaboratoriesInc
    • Invivoscribe
    • Leica Biosystems
    • AffymetrixInc
    • Qiagen NV
    • BD（Becton, Dickinson And Company）
    • Agilent TechnologiesInc
    • Genomic Health
    • Sysmex Corporation
    • Beckman CoulterInc
    • Thermo Fisher Scientific Inc
    • IlluminaInc
簡介目錄
Product Code: VMR11216669

The Fusion Biopsy Market size is expected to reach USD 2.98 Billion in 2034 from USD 1.45 Billion (2025) growing at a CAGR of 8.3% during 2026-2034.

The fusion biopsy market is experiencing significant growth, driven by advancements in imaging technologies and the increasing prevalence of prostate cancer. Fusion biopsy combines traditional ultrasound imaging with magnetic resonance imaging (MRI) to enhance the accuracy of prostate cancer diagnosis. This innovative approach allows for targeted sampling of suspicious lesions, improving the detection rate of clinically significant cancers while minimizing unnecessary biopsies. As awareness of prostate cancer rises and screening guidelines evolve, the demand for fusion biopsy procedures is expected to increase, positioning this market for robust expansion.

Moreover, the growing emphasis on personalized medicine is influencing the fusion biopsy landscape. By providing more precise information about tumor characteristics, fusion biopsy enables healthcare providers to tailor treatment plans to individual patients. This shift towards targeted therapies is particularly relevant in oncology, where understanding the specific biology of a tumor can significantly impact treatment outcomes. As healthcare systems increasingly adopt precision medicine approaches, the fusion biopsy market is likely to benefit from the integration of advanced diagnostic tools that enhance patient care and optimize resource utilization.

Additionally, the rise of minimally invasive procedures is driving the adoption of fusion biopsy techniques. Patients are increasingly seeking options that reduce discomfort and recovery time, making fusion biopsy an attractive alternative to traditional biopsy methods. The development of user-friendly devices and training programs for healthcare professionals is further facilitating the adoption of this technology. As the fusion biopsy market continues to evolve, ongoing research and innovation will play a crucial role in expanding its applications and improving diagnostic accuracy, ultimately contributing to better patient outcomes in the fight against prostate cancer.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Tech Target

  • DNA
  • RNA
  • Protein

By Product

  • Multi-gene Panels
  • Single-gene Tests
  • Companion Diagnostics
  • Research Use Only (RUO) Kits

By Application

  • Oncology
  • Neurology
  • Infectious Diseases
  • Cardiovascular Diseases

By Technology

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Digital PCR
  • NanoString Technologies

COMPANIES PROFILED

  • Hologic, Inc, Exact Sciences Corporation, Myriad Genetics, Inc, BioRad Laboratories, Inc, Invivoscribe, Leica Biosystems, Affymetrix, Inc, Qiagen NV, BD Becton, Dickinson and Company, Agilent Technologies, Inc, Genomic Health, Sysmex Corporation, Beckman Coulter, Inc, Thermo Fisher Scientific Inc, Illumina, Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL FUSION BIOPSY MARKET: BY TECH TARGET 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Tech Target
  • 4.2. DNA Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. RNA Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Protein Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL FUSION BIOPSY MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Product
  • 5.2. Multi-gene Panels Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Single-gene Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Companion Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Research Use Only (RUO) Kits Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL FUSION BIOPSY MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Application
  • 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Cardiovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL FUSION BIOPSY MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Technology
  • 7.2. Next-Generation Sequencing (NGS) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Polymerase Chain Reaction (PCR) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Digital PCR Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. NanoString Technologies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL FUSION BIOPSY MARKET: BY REGION 2022-2034(USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Tech Target
    • 8.2.2 By Product
    • 8.2.3 By Application
    • 8.2.4 By Technology
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Tech Target
    • 8.3.2 By Product
    • 8.3.3 By Application
    • 8.3.4 By Technology
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Tech Target
    • 8.4.2 By Product
    • 8.4.3 By Application
    • 8.4.4 By Technology
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Tech Target
    • 8.5.2 By Product
    • 8.5.3 By Application
    • 8.5.4 By Technology
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 South East Asia
    • 8.5.10 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Tech Target
    • 8.6.2 By Product
    • 8.6.3 By Application
    • 8.6.4 By Technology
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL FUSION BIOPSY INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 HologicInc
    • 10.2.2 Exact Sciences Corporation
    • 10.2.3 Myriad GeneticsInc
    • 10.2.4 BioRad LaboratoriesInc
    • 10.2.5 Invivoscribe
    • 10.2.6 Leica Biosystems
    • 10.2.7 AffymetrixInc
    • 10.2.8 Qiagen N.V
    • 10.2.9 BD (Becton, Dickinson And Company)
    • 10.2.10 Agilent TechnologiesInc
    • 10.2.11 Genomic Health
    • 10.2.12 Sysmex Corporation
    • 10.2.13 Beckman CoulterInc
    • 10.2.14 Thermo Fisher Scientific Inc
    • 10.2.15 IlluminaInc